These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 24085845)

  • 21. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
    Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
    Wang L; Wang Q; Xu Y; Cui M; Han L
    Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
    Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
    Bowman-Colin C; Xia B; Bunting S; Klijn C; Drost R; Bouwman P; Fineman L; Chen X; Culhane AC; Cai H; Rodig SJ; Bronson RT; Jonkers J; Nussenzweig A; Kanellopoulou C; Livingston DM
    Proc Natl Acad Sci U S A; 2013 May; 110(21):8632-7. PubMed ID: 23657012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling Therapy Resistance in
    Dréan A; Williamson CT; Brough R; Brandsma I; Menon M; Konde A; Garcia-Murillas I; Pemberton HN; Frankum J; Rafiq R; Badham N; Campbell J; Gulati A; Turner NC; Pettitt SJ; Ashworth A; Lord CJ
    Mol Cancer Ther; 2017 Sep; 16(9):2022-2034. PubMed ID: 28619759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
    Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
    Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation.
    Zong D; Adam S; Wang Y; Sasanuma H; Callén E; Murga M; Day A; Kruhlak MJ; Wong N; Munro M; Ray Chaudhuri A; Karim B; Xia B; Takeda S; Johnson N; Durocher D; Nussenzweig A
    Mol Cell; 2019 Mar; 73(6):1267-1281.e7. PubMed ID: 30704900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
    Cong K; Peng M; Kousholt AN; Lee WTC; Lee S; Nayak S; Krais J; VanderVere-Carozza PS; Pawelczak KS; Calvo J; Panzarino NJ; Turchi JJ; Johnson N; Jonkers J; Rothenberg E; Cantor SB
    Mol Cell; 2021 Aug; 81(15):3128-3144.e7. PubMed ID: 34216544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations.
    Park PH; Yamamoto TM; Li H; Alcivar AL; Xia B; Wang Y; Bernhardy AJ; Turner KM; Kossenkov AV; Watson ZL; Behbakht K; Casadei S; Swisher EM; Mischel PS; Johnson N; Bitler BG
    Mol Cancer Ther; 2020 Feb; 19(2):602-613. PubMed ID: 31575654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
    Stordal B; Timms K; Farrelly A; Gallagher D; Busschots S; Renaud M; Thery J; Williams D; Potter J; Tran T; Korpanty G; Cremona M; Carey M; Li J; Li Y; Aslan O; O'Leary JJ; Mills GB; Hennessy BT
    Mol Oncol; 2013 Jun; 7(3):567-79. PubMed ID: 23415752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
    Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
    Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing.
    Zhao W; Steinfeld JB; Liang F; Chen X; Maranon DG; Jian Ma C; Kwon Y; Rao T; Wang W; Sheng C; Song X; Deng Y; Jimenez-Sainz J; Lu L; Jensen RB; Xiong Y; Kupfer GM; Wiese C; Greene EC; Sung P
    Nature; 2017 Oct; 550(7676):360-365. PubMed ID: 28976962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compensatory functions and interdependency of the DNA-binding domain of BRCA2 with the BRCA1-PALB2-BRCA2 complex.
    Al Abo M; Dejsuphong D; Hirota K; Yonetani Y; Yamazoe M; Kurumizaka H; Takeda S
    Cancer Res; 2014 Feb; 74(3):797-807. PubMed ID: 24285729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.
    Zhang F; Fan Q; Ren K; Andreassen PR
    Mol Cancer Res; 2009 Jul; 7(7):1110-8. PubMed ID: 19584259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
    Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCAness revisited.
    Lord CJ; Ashworth A
    Nat Rev Cancer; 2016 Feb; 16(2):110-20. PubMed ID: 26775620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
    Wang W; Figg WD
    Cancer Biol Ther; 2008 Jul; 7(7):1004-5. PubMed ID: 18720553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
    Węsierska-Gądek J; Zulehner N; Ferk F; Składanowski A; Komina O; Maurer M
    Biochem Pharmacol; 2012 Nov; 84(10):1318-31. PubMed ID: 22906755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.